LARIMAR THERAPEUTICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
LARIMAR THERAPEUTICS, INC. (LRMR) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $3.59 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-04
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $3.61, a 4.64% increase year-over-year.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $3.45, a 21.95% decline year-over-year.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $4.42, a 12.65% decline year-over-year.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $5.06, a 42.57% decline year-over-year.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $5.35, a 14.32% increase from fiscal 2023.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $4.68, a 32.56% decline from fiscal 2022.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $6.94, a 55.40% decline from fiscal 2021.
- LARIMAR THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2021 was $15.56, a 26.09% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.59 10-Q · filed 2026-08-04 | |||
| 2026-03-31 | $3.61 10-Q · filed 2026-05-14 | |||
| 2025-09-30 | $3.33 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $3.32 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | $3.45 10-Q · filed 2025-04-30 | |||
| 2024-12-31 | $5.35 10-K · filed 2025-03-24 | |||
| 2024-09-30 | $5.22 10-Q · filed 2024-10-30 | |||
| 2024-06-30 | $5.05 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $4.42 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $4.68 10-K · filed 2024-03-14 | |||
| 2023-09-30 | $4.73 10-Q · filed 2023-11-14 | |||
| 2023-06-30 | $4.93 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | $5.06 10-Q · filed 2023-05-15 | |||
| 2022-12-31 | $6.94 10-K · filed 2023-03-14 | |||
| 2022-09-30 | $6.99 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | $7.08 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | $8.81 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | $15.56 10-K · filed 2022-03-25 | |||
| 2021-09-30 | $15.62 10-Q · filed 2021-11-12 | |||
| 2021-06-30 | $15.74 10-Q · filed 2021-08-12 | |||
| 2021-03-31 | $18.70 10-Q · filed 2021-05-10 | |||
| 2020-12-31 | $12.34 10-K · filed 2021-03-04 | |||
| 2020-09-30 | $11.96 10-Q · filed 2020-11-12 | |||
| 2020-06-30 | $11.88 10-Q · filed 2020-08-14 | |||
| 2019-09-30 | $4.00 10-Q · filed 2019-11-06 | |||
| 2016-12-31 | $6.65 10-K · filed 2017-03-10 | |||
| 2015-12-31 | $39.37 10-K · filed 2016-03-15 | |||
| 2014-12-31 | $15.56 10-K · filed 2015-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |